Shots:
Rezolute has completed enrolment in the P-III (upLIFT) trial assessing ersodetug in 16 pts with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI), with topline data expected mid-Dec 2026
Earlier this year, 7 of 8 pts enrolled in the study’s first half met the 1EP responder criterion, with…
